Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.
Abstract
The opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling. Aberrant transcription due to altered expression or mutation of genes that encode HATs, HDACs or their binding partners, is a key event in the onset and progression of cancer. HDAC inhibitors can reactivate gene expression and inhibit the growth and survival of tumour cells. The remarkable tumour specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylation of the core histones of nucleosomes strongly influences gene transcription (Khochbin et al., 2001; Johnstone, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Class I HDACs are ubiquitously expressed and are primarily located in the nucleus, while the class II enzymes can shuttle between the nucleus and cytoplasm and demonstrate tissue-specific expression (Johnstone, 2002; Marks et al., 2001; Vigushin and Coombes, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Two related classes of eukaryotic zinc-containing HDACs have been recognized based upon sequence similarity: class I (HDAC1, 2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) (Johnstone, 2002; Gao et al., 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“In general terms, condensed chromatin mediates transcriptional repression, whereas transcriptionally active genes are in areas of open chromati”
BackgroundCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“pl?locus=sir2">Sir2 , a yeast transcriptional repressor that requires the cofactor NAD + for its deacetylase activit”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“gov/cancer_information/cancer_type/leukemia/">leukaemias and solid tumours to express differentiated characteristics and stop proliferatin”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780 · cited 5×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundInfluential
Research works printed but not linked: 1
- Ruefli, A. A. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-gp expressing cells. Int. J. Cancer. (in the press).
Cited by
Items 801–900 of 1,001
Quantification of Plasma or Serum Short-Chain Fatty Acids: Choosing the Correct Blood Tube
Verbeke, K. (2017) · Journal of Nutritional Health & Food Science · doi:10.15226/jnhfs.2017.001112 · Cited by 38
“The fact that SCFA, in particular butyrate and to a lesser extent propionate inhibit histone deacetylases and in this way impact on the expression of genes with functions including cell proliferation, inflammation and apoptosis, may explain at least part of their effect [9].”
BackgroundNaldi, M., Andrisano, V., Fiori, J., Calonghi, N., Pagnotta, E., Parolin, C., Pieraccini, G., & Masotti, L. (2006) · Journal of Chromatography A · doi:10.1016/j.chroma.2006.06.100 · Cited by 31
Khan, Z. I., Akhtar, M., Asklund, T., Juliusson, B., Almqvist, P. M., & Ekström, T. J. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.05.004 · Cited by 29
Li, X., Li, M., Chen, J., Dai, H., Wang, L., Xiong, Y., Zhong, Y., & Zhang, L. (2017) · Oncotarget · doi:10.18632/oncotarget.21792 · Cited by 29
“As we know, tumorigenesis is a process of pathological chromatin remodeling, and many remodeling complexes showed abnormal expression levels along with tumorigenesis [41], including BRG1 [42], HDAC1/2 [43], BPTF [14].”
BackgroundRetractedXiao, M., Liu, Y. G., Zou, M. C., & Zou, F. (2014) · PubMed · doi:10.3967/bes2014.040 · Cited by 28
Tickenbrock, L., Klein, H., Trento, C., Hascher, A., Göllner, S., Bäumer, N., Kuss, R., Agrawal, S., Bug, G., Serve, H. L., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.11.006 · Cited by 31
Mechanisms of transcription factor acetylation and consequences in hearts
Thiagarajan, D., Vedantham, S., Ananthakrishnan, R., Schmidt, A. M., & Ramasamy, R. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.011 · Cited by 31
“HATs and HDACs play an important role in regulating cardiac hypertrophy [47-50].”
BackgroundOroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression
Huo, T., Wang, X., Yu, Z., Kong, B., He, Y. Z., Guo, Q., Zhang, X., & Qiang, L. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00695-4 · Cited by 28
Bedi, Y. S., Roach, A. N., Thomas, K. N., Mehta, N. A., & Golding, M. C. (2022) · Epigenetics & Chromatin · doi:10.1186/s13072-021-00433-4 · Cited by 34
“This family is divided into three classes based on their exclusive localization to the nucleus (Class I), their ability to shuttle between the cytoplasm and the nucleus (Class II), and if they require the cofactor NAD + for deacetylase activity (Class III) [40].”
BackgroundLiang, M., Tang, Q., Zhong, J., & Ai, Y. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115086 · Cited by 30
Parsana, N., Ukani, H., Chauhan, D. S., Seoud, O. A. E., Mehra, S., Kumar, A., Raje, N. H., & Malek, N. I. (2024) · RSC Pharmaceutics · doi:10.1039/d3pm00088e · Cited by 28
High‐Content Fluorescence‐Based Screening for Epigenetic Modulators
Martínez, E. D., Dull, A. B., Beutler, J. A., & Hager, G. L. (2006) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(06)14002-1 · Cited by 30
Different effect of sodium butyrate on cancer and normal prostate cells
Pašková, L., Trtková, K. S., Fialova, B., Benedíková, A., Langová, K., & Kolář, Z. (2013) · Toxicology in Vitro · doi:10.1016/j.tiv.2013.03.002 · Cited by 29
Inhibition of tumor–stromal interaction through HGF/Met signaling by valproic acid
Matsumoto, Y., Motoki, T., Kubota, S., Takigawa, M., Tsubouchi, H., & Gohda, E. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.089 · Cited by 28
“HDAC inhibitors induce proliferation arrest, differentiation, and/or apoptosis of tumor cells but not of normal cells [17].”
BackgroundKumai, T., Ishibashi, K., Oikawa, K., Matsuda, Y., Aoki, N., Kimura, S., Hayashi, S., Kitada, M., Harabuchi, Y., Celis, E., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1533-z · Cited by 30
Targeting histone deacetylase in thyroid cancer
Russo, D., Durante, C., Bulotta, S., Puppin, C., Puxeddu, E., Filetti, S., & Damante, G. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.740013 · Cited by 31
“Depsipeptide (FK228 or romidepsin) is a cyclic peptide that inhibits HDAC activity at nanomolar concentrations [60].”
BackgroundCosner, C. C., & Helquist, P. M. (2011) · Organic Letters · doi:10.1021/ol200964m · Cited by 30
Abo-Elfadl, M. T., Gamal‐Eldeen, A. M., Elshafey, M. M., Abd‐Alla, G. M., Ali, S. S., Ali, M. R. K., & Zawrah, M. F. (2016) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2016.09.012 · Cited by 28
CpG Island Methylation and Histone Modifications: Biology and Clinical Significance
Esteller, M. (2006) · Springer eBooks · doi:10.1007/3-540-37633-x_7 · Cited by 28
Roychowdhury, S., Baiocchi, R. A., Vourganti, S., Bhatt, D., Blaser, B. W., Freud, A. G., Chou, J., Chen, C., Xiao, J. J., Parthun, M. R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh271 · Cited by 28
“Compounds with histone deacetylase inhibitor activity induce growth arrest, differentiation, and apoptosis in various tumor cell lines in vitro and in several preclinical animal models of cancer ( 3 ).”
BackgroundCampanero, M. R., Herrero, A., & Calvo, V. (2007) · Oncogene · doi:10.1038/sj.onc.1210735 · Cited by 28
“…Madrid, Spain), induce many genes coding for proteins involved in cell cycle control, including GADD45a and GADD45b (Della-Ragione et al., 2001; Chen et al., 2002; Hirose et al., 2003), and stop tumor growth by eliciting either cell cycle arrest or apoptosis in tumor cells (Johnstone, 2002).”
BackgroundYang, Y., Liu, K., Liang, Y., Chen, Y., Chen, Y., & Gong, Y. (2015) · PubMed Central · Cited by 27
Comparative Modeling and Benchmarking Data Sets for Human Histone Deacetylases and Sirtuin Families
Xia, J., Tilahun, E. L., Kebede, E. H., Reid, T.-E. R., Zhang, L., & Wang, X. S. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci5005515 · Cited by 30
A novel embryotoxic estimation method of VPA using ES cells differentiation system
Murabe, M., Yamauchi, J., Fujiwara, Y., Hiroyama, M., Sanbe, A., & Tanoue, A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.189 · Cited by 27
Jones, A., Lechner, M., Fourkala, E.-O., Kristeleit, R. S., & Widschwendter, M. (2010) · Epigenomics · doi:10.2217/epi.09.47 · Cited by 28
Histone Deacetylases and Their Role in Asthma
Royce, S. G., & Karagiannis, T. C. (2012) · Journal of Asthma · doi:10.3109/02770903.2011.648298 · Cited by 28
Wang, Y., Yang, X., Xing, L., & Kong, W.-Z. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i31.5159 · Cited by 28
VanOosten, R. L., Earel, J. K., & Griffith, T. S. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700939 · Cited by 27
Retinoblastoma epidemiology: Does the evidence matter?
Mastrangelo, D., Francesco, S. D., Leonardo, A. D., Lentini, L., & Hadjistilianou, T. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.04.019 · Cited by 31
Konsoula, Z., Cao, H., Velena, A., & Jung, M. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0629 · Cited by 27
Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro
ZHOU, Y., Xu, Y. X., Wang, H., NIU, J., Hou, H., & Jiang, Y. (2013) · Oncology Letters · doi:10.3892/ol.2013.1666 · Cited by 28
“Accordingly, HDACIs have been shown, in a preclinical setting, to be effective anticancer agents via multiple mechanisms, including the induction of cell cycle arrest, intrinsic and extrinsic apoptotic mechanisms, autophagic cell death, mitotic cell death, the generation of reactive oxygen species, the inhibition of a…”
BackgroundDesign, synthesis and biological evaluation of novel hydroxamic acids bearing artemisinin skeleton
Hà, V. T. T., Kien, V. T., Binh, L. H., Tiến, V. Đ., My, N. T. T., Nam, N., Baltas, M., Hahn, H., Han, B. W., Thảo, Đ. T., et al. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.03.008 · Cited by 29
Ma, T., Huang, C. Z., Meng, X., Li, X., Zhang, Y., Ji, S., Li, J., Ye, M., & Liang, H. (2016) · Scientific Reports · doi:10.1038/srep25396 · Cited by 27
Gromek, S. M., deMayo, J. A., Maxwell, A. T., West, A. M., Pavlik, C. M., Zhao, Z., Li, J., Wiemer, A. J., Zweifach, A., & Balunas, M. J. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.08.040 · Cited by 30
Potential of epigenetic events in human thyroid cancer
Ahmed, A. A., & Essa, M. E. A. (2019) · Cancer Genetics · doi:10.1016/j.cancergen.2019.08.006 · Cited by 30
Cao, Z. A., Bass, K. E., Balasubramanian, S., Liu, L., Schultz, B. E., Verner, E. J., Dai, Y., Molina, R. A., Davis, J. R., Misialek, S., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0042 · Cited by 29
“HDAC1 and HDAC2 form part of the transcription repression complex SIN3-HDAC and the nucleosome remodeling deacetylase complex NuRD-Mi2-NRD (13).”
Ian, M. T. (2006) · Frontiers in bioscience · doi:10.2741/2079 · Cited by 29
“Such compounds are currently in both preclinical development and clinical trials (28).”
BackgroundZhou, X., Yang, X.-Y., & Popescu, N. C. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.02.158 · Cited by 26
Epigenetic “Drivers” of Cancer
Butera, A., Melino, G., & Amelio, I. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167094 · Cited by 32
Nutrigenetics and nutrigenomics—A personalized approach to nutrition
Ahluwalia, M. K. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.005 · Cited by 31
Modification of cap group in δ-lactam-based histone deacetylase (HDAC) inhibitors
Kim, H. M., Hong, S. H., Kim, M. S., Lee, C. W., Kang, J. S., Lee, K., Park, S., Han, J. W., Lee, H. Y., Choi, Y., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.034 · Cited by 26
Characterization of valproic acid‐initiated homologous recombination
Sha, K., & Winn, L. M. (2010) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.20236 · Cited by 29
“Abbrevations: HAT, histone acetyl-transferase; HDAC, histone deacetylase; ME, methyl group; P, phosphoryl group, Ac, acetyl group; MECP2, methylCpG-binding protein, SIN3A, SIN3 homolog A (modified from Johnstone, 2002).”
Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells
Iacopino, F., Urbano, R., Graziani, G., Muzi, A., Pierluigi, N., & Sica, G. (1992) · International Journal of Oncology · doi:10.3892/ijo_32_6_1293 · Cited by 28
“developed as a new class of anti-cancer agents (1,2).”
BackgroundDrug repurposing in malignant pleural mesothelioma: a breath of fresh air?
Boyer, A., Pasquier, E., Tomasini, P., Ciccolini, J., Greillier, L., André, N., Barlési, F., & Mascaux, C. (2018) · European Respiratory Review · doi:10.1183/16000617.0098-2017 · Cited by 33
Wine pomace product modulates oxidative stress and microbiota in obesity high-fat diet-fed rats
Gerardi, G., Cavia-Sáiz, M., Rivero-Perez, M. D., José, M., & Múñiz, P. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.103903 · Cited by 26
Antiproliferative effect of trichostatin a and hc-toxin in T47D Human breast cancer cells
Joung, K. E., Kim, D., & Sheen, Y. Y. (2004) · Archives of Pharmacal Research · doi:10.1007/bf02980164 · Cited by 26
Wu, P., Tian, Y. E., Chen, G., Wang, B., Gui, L., Xi, L., Ma, X., Fang, Y., Zhu, T., Wang, D., et al. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.142 · Cited by 27
“extended our understanding of the action of HDACis, some basic questions still remain to be addressed.(8,9) One of the obviously unanswered questions is whether a universal, essential target responsible for HDACi-mediated apoptosis exists.”
BackgroundHan, S., Fukazawa, T., Yamatsuji, T., Matsuoka, J., Miyachi, H., Maeda, Y., Durbin, M. L., & Naomoto, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013834 · Cited by 28
“Nonselective inhibitors of human histone deacetylases (HDAC) are reported to have antitumor activity in vivo, and several of them are under clinical trials [9,28,29,30,31,32,33,34,35,36].”
BackgroundHerman, A., & Bajaka, A. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113923 · Cited by 32
Chaudhuri, S., Fowler, M. J., Baker, C., Stopka, S. A., Regan, M. S., Sablatura, L. K., Broughton, C. W., Knight, B. E., Stabenfeldt, S. E., Agar, N. Y. R., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c22587 · Cited by 26
“acetylation of core histones, leading to relaxation of chromatin and therapeutic effects in a multitude of disease models.(1-10) Unfortunately, utility of HDACi is plagued by delivery problems, including rapid clearance and poor tissue distribution when molecules are administered in free form.”
Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network
Shankar, T. V. S., & Willems, L. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.01.003 · Cited by 27
Politis, P. K., Akrivou, S., Hurel, C., Papadodima, O., & Matsas, R. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.01.052 · Cited by 25
“Many different inhibitors of these enzymes have been developed and are currently considered for therapeutic strategies [1,6,7].”
BackgroundProtein acetylation within the cellular response to radiation
Averbeck, N., & Durante, M. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22466 · Cited by 27
“Dysfunction and mutation of KATs as well as KDACs are connected to cancer (Johnstone, 2002), and therefore inhibitors of these enzymes can play a role in cancer treatment.”
BackgroundKinugasa, F., Nagatomi, I., Nakanishi, T., Noto, T., Mori, H., Matsuoka, H., Sudo, Y., & Mutoh, S. (2009) · Transplant Immunology · doi:10.1016/j.trim.2009.04.006 · Cited by 25
Patra, N., De, U., Kim, T. H., Lee, Y. J., Ahn, M. Y., Kim, N. D., Yoon, J. H., Choi, W. S., Moon, H. R., Lee, B. M., et al. (2013) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2013.01.006 · Cited by 25
“followed by the release of cytochrome c and other pro-apoptotic molecules into the cytoplasm [43].”
BackgroundNaldi, M., Calonghi, N., Masotti, L., Parolin, C., Valente, S., Mai, A., & Andrisano, V. (2009) · PROTEOMICS · doi:10.1002/pmic.200800866 · Cited by 25
Trichostatin A Promotes the Generation and Suppressive Functions of Regulatory T Cells
Doñas, C., Fritz, M., Manríquez, V., Tejón, G., Bono, M. R., Loyola, A., & Rosemblatt, M. S. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/679804 · Cited by 25
Renzo, F. D., Broccia, M. L., Giavini, E., & Menegola, E. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm115 · Cited by 27
“As the acetylation status of histone lysine residues plays a crucial role in modulating chromatin structure and gene transcription, the antitumoral activity of HDACi has been classically related to chromatin condensation and consequently to an altered gene expression in tumor-inducing growth arrest, differentiation, a…”
BackgroundBiotechnological potential of marine natural products
Fusetani, N. (2010) · Pure and Applied Chemistry · doi:10.1351/pac-con-09-01-11 · Cited by 25
Epithelial–mesenchymal transition in pulmonary carcinosarcoma: case report and literature review
Thomas, V. T., Hinson, S., & Konduri, K. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011421949 · Cited by 25
“HDAC inhibitors are an emerging class of therapeutic agents that can reactivate gene expression and inhibit the growth and survival of tumor cells [Johnstone, 2002].”
BackgroundEpigenetics and innate immunity: the ‘unTolld’ story
Hennessy, C., & McKernan, D. P. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.24 · Cited by 28
Effect of small molecules on cell reprogramming
Baranek, M., Belter, A., Naskręt-Barciszewska, M. Z., Stobiecki, M., Markiewicz, W. T., & Barciszewski, J. (2016) · Molecular BioSystems · doi:10.1039/c6mb00595k · Cited by 26
Chao, S.-W., Chen, L., Yu, C.-C., Liu, C., Lin, T. E., Guh, J., Wang, C.-Y., Chen, C.-Y., Hsu, K., & Huang, W. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.092 · Cited by 26
Shen, W. T., & Chung, W.-Y. (2005) · Thyroid · doi:10.1089/thy.2005.15.594 · Cited by 25
“Histones are nuclear proteins that organize DNA into nucleosomes, which are the repeating structural elements in nuclear chromatin (6,7).”
InfluentialThe discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay
Xia, J., Hu, H., Xue, W., Wang, X. S., & Wu, S. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1437156 · Cited by 24
Nuclear proteins as gene-transfer vectors
Haberland, A., & Böttger, M. (2005) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20050063 · Cited by 24
Histone Deacetylase Inhibitors: Emerging Anticancer Therapeutic Agents?
Kristeleit, R. S., Fong, P. C. C., Aherne, G. W., & Bono, J. S. D. (2005) · Clinical Lung Cancer · doi:10.3816/clc.2005.s.004 · Cited by 25
Praseetha, S., Bandaru, S., Nayarisseri, A., & Sureshkumar, S. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.3.1571 · Cited by 24
Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer
McCaw, T. R., Goel, N., Brooke, D. J., Katre, A. A., Londoño, A. I., Smith, H. J., Randall, T. D., & Arend, R. C. (2020) · Cancer Medicine · doi:10.1002/cam4.3337 · Cited by 27
The role of viruses in cancer development versus cancer therapy: An oncological perspective
Javid, H., Mashhad, A. S., Yazdani, S., Oryani, M. A., Akbari, S., Rezagholinejad, N., Tajaldini, M., & Karimi‐Shahri, M. (2023) · Cancer Medicine · doi:10.1002/cam4.5694 · Cited by 28
Pansuriya, R., Mehra, S., Kumar, A., Seoud, O. A. E., Kailasa, S. K., & Malek, N. I. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.121857 · Cited by 24
Sun, L., Wan, A. H., Yan, S., Liu, R., Li, J., Zhou, Z., Wu, R., Chen, D., Bu, X., Ou, J., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.09.015 · Cited by 26
“Previous studies have reported romidepsin enhancing immunogenicity of tumor cells, thereby improving clinical efficacy 29,30 .”
BackgroundChuang, C.-M., Chang, C.-H., Wang, H.-E., Chen, K. C., Peng, C. C., Hsieh, C. L., & Peng, R. Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043692 · Cited by 24
“For example, superoxide reacts with NO radicals (NNO) to produce toxic PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e43692 peroxynitrite (OONO2), which can be very detrimental to many biomolecules including DNA, RNA, enzymes, and a diversity of signaling peptides [27]; the result is an indirect o…”
BackgroundPolyamine-based analogues as biochemical probes and potential therapeutics
Boncher, T. D., Bi, X., Varghese, S., Casero, R. A., & Woster, P. M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350356 · Cited by 24
Renzo, F. D., Cappelletti, G., Broccia, M. L., Giavini, E., & Menegola, E. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn094 · Cited by 24
“The most susceptible histones to epigenetical modifications by acetylation/deacetylation are H3 and H4 (Johnstone, 2002).”
BackgroundHistone Deacetylase Inhibitor: Antineoplastic Agent and Radiation Modulator
Konsoula, Z., Velena, A., Lee, R., Dritschilo, A., & Jung, M. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0254-1_14 · Cited by 27
“Moreover, changes in the chromatin architecture by HDACI have shown to enhance the activation of nonhis-tone proteins, including p53, pRB, and transcriptional factors that are involved in cell cycle regulation and affect cell proliferation and apoptosis, processes that are frequently aberrant in cancers [11, 35].”
BackgroundHistone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry.
Chung, E. J., Lee, S., Sausville, E. A., Ryan, Q. C., Karp, J. E., Gojo, I., Telford, W. G., Lee, M. J., Kong, H. S., & Trepel, J. B. (2005) · PubMed · Cited by 24
Highly fluorescent and HDAC6 selective scriptaid analogues
Fleming, C. L., Natoli, A. L., Schreuders, J., Devlin, M. G., Yoganantharajah, P., Gibert, Y., Leslie, K. G., New, E. J., Ashton, T. D., & Pfeffer, F. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.020 · Cited by 25
Sanaei, M., Kavoosi, F., Roustazadeh, A., & Shahsavani, H. (2018) · PubMed Central · doi:10.22034/apjcp.2018.19.9.2507 · Cited by 27
“Histone deacetylase inhibitors (HDACIs) are a class of chemotherapeutic agent that can reactivate gene expression and inhibit the growth of tumor cells and also induce apoptosis in a wide range of tumor-derived cell lines by histone deacetylase inhibition (Marks et al., 2001; Johnstone, 2002).”
BackgroundMukhopadhyay, U., Tong, W. P., Gelovani, J. G., & Alauddin, M. M. (2006) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.1122 · Cited by 24
Yang, W., Li, L., Ji, X., Wu, X., Su, M., Li, S., Zang, Y., Li, J. X., & Liu, H. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.08.030 · Cited by 24
Deregulated Chromatin Remodeling in the Pathobiology of Brain Tumors
Spyropoulou, A., Piperi, C., Adamopoulos, C., & Papavassiliou, A. G. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8205-y · Cited by 26
Sasaki, Y., Negishi, H., Idogawa, M., Suzuki, H., Mita, H., Toyota, M., Shinomura, Y., Imai, K., & Tokino, T. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0395 · Cited by 27
“expression of which potentially causes inhibition of tumor cell growth (16).”
BackgroundAcetylation and Histone Deacetylase Inhibitors in Cancer
Kortenhorst, M. S. Q., Carducci, M. A., & Shabbeer, S. (2006) · Analytical Cellular Pathology · doi:10.1155/2006/760183 · Cited by 27
“HDACIs can also increase expression of pro-apoptotic genes such as Bak, Bax, CD95, CD95 ligand, gelsolin, p53, GADD45 β, DRAK1, Apaf-1, DFF45 α, caspase-9, caspase-8, caspase-3, Bim, Bid and Bad, and decrease expression of anti-apoptotic genes including Bcl-2, Bcl-xL, c-FLIP, survivin, XIAP, Mcl-1 and NFκB [3,44,62,91…”
BackgroundLuz-Madrigal, A., Clapp, C., Aranda, J., & Vaca, L. A. (2007) · Virology Journal · doi:10.1186/1743-422x-4-88 · Cited by 25
“To date 17 human genes have been identified encoding HDACs, 11 of these genes, members of so-called clase I and II, are inhibited by TSA [35].”
BackgroundTang, S., Ma, D., Cheng, B., Fang, Q., Kuang, X., Yu, K., Wang, W., Hu, B., & Wang, J. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.01.005 · Cited by 23
Ilayaperumal, P., Chelladurai, P., Vairan, K., Anilkumar, P., & Balagurusamy, B. (2023) · Macromolecular Materials and Engineering · doi:10.1002/mame.202200553 · Cited by 27
Jin, L., & Datta, P. K. (2014) · Cell Cycle · doi:10.4161/15384101.2014.973310 · Cited by 24
“HDAC inhibitors.(34) However, little is known about the mechanism of how p21 might be regulated by HDACs through Sp1.”
BackgroundKhare, S., Sharma, A. K., Deodhar, K., & Gupta, S. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2010.010140 · Cited by 23
Kinugasa, F., Yamada, T., Noto, T., Matsuoka, H., Mori, H., Sudo, Y., & Mutoh, S. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.1723 · Cited by 23
Lin, K., Yeh, S., Chen, D., Chen, P., & Jou, Y. (2005) · Journal of Biomedical Science · doi:10.1007/s11373-005-9005-2 · Cited by 23
The Changing Face of HDAC Inhibitor Depsipeptide
Zhou, W., & Zhu, W. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787314039 · Cited by 24
“Depsipeptide has demonstrated strong potential for clinical treatment of cancer in a number of studies carried out in vitro with tumor cell lines and in vivo with human tumor graft or mouse tumors [2, 10, 99-101].”
BackgroundLiu, D., Andrade, S. P., Castro, P. R., Treacy, J., Ashworth, J., & SLEVIN, M. A. (2016) · Scientific Reports · doi:10.1038/srep34649 · Cited by 27
Negmeldin, A. T., & Pflum, M. K. H. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.06.033 · Cited by 24
Histone deacetylase activity mediates thermal plasticity in zebrafish (Danio rerio)
Seebacher, F., & Simmonds, A. I. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-44726-x · Cited by 26
Histone deacetylase‑2: A potential regulator and therapeutic target in liver disease (Review)
Liu, Y.-R., Wang, J., Huang, Z., Chen, R.-N., Cao, X., Zhu, D., Yu, H., Wang, X., Zhou, H.-Y., Xia, Q., et al. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4964 · Cited by 27
“class II HdAcs can be separated into class IIa (HdAcs 4, 5, 7 and 9) and IIb (HdAcs 6 and 10), depending on the presence of tandem deacetylase domains (41,52).”
BackgroundSelection of an improved HDAC8 inhibitor through structure-based drug design
Balakrishnan, V., Umamaheswari, A., Puratchikody, A., & Velmurugan, D. (2011) · Bioinformation · doi:10.6026/97320630007134 · Cited by 27
Design of polyamine-based therapeutic agents: new targets and new directions
Senanayake, T., Amunugama, H., Boncher, T. D., Casero, R. A., & Woster, P. M. (2009) · Essays in Biochemistry · doi:10.1042/bse0460006 · Cited by 23
“HDAC inhibitors such as TSA (trichostatin A), MS-275 {N-(2- aminophenyl) -4-[N-(pyridin-3-ylmethoxycarbonyl)-ami nomethyl]benzamide} and SAHA (suberoylanilide hydroxamic acid) can cause growth arrest in a wide range of transformed cells, and can inhibit the growth of human tumour xenografts [52].”
InfluentialRodríguez-Salvador, J., Armas-Pineda, C., Pérezpeña-Díazconti, M., Chico-Ponce de León, F., Sosa-Sáinz, G., Lezama, P., Targa, F. R., & Arenas‐Huertero, F. (2005) · PubMed · Cited by 25
Zhang, J., Wong, H., Ramanan, S., Cheong, D., Leong, A. F. P. K., & Hooi, S. C. (2003) · PubMed · Cited by 29
Metadata
- Authors
- Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971621147
- Cited by
- 1,515
- References
- 121
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 23 · 2023: 46 · 2022: 35 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 38 · 2017: 65 · 2016: 50 · 2015: 64 · 2014: 54 · 2013: 81 · 2012: 94
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, aberrant transcription, tumor cell growth inhibition, cancer therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Cell Differentiation, Chromatin, Clinical Trials as Topic, Enzyme Inhibitors, Histones, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.